retatrutide data BioCentury 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

Diabetes also is associated with more rapid progression of Parkinsons symptoms in people who have both diseases

14 Recommendations The results above have prompted the ADA and EASD to recommend GLP-1RAs as preferred second- or third-line injectable agents following metformin in people with: 1 established atherosclerotic cardiovascular disease a need to minimise weight gain or promote weight loss a need to minimise hypoglycaemia mild-to-moderate chronic kidney disease

There's also a larger question hanging over the Medicare breakthrough: Unless the Trump administration extends or replaces the demonstration program, obesity drug coverage is scheduled to expire at the end of 2027

GLP-1-based therapies: the dilemma of uncertainty

& Gruessner, A